|
Malignant neoplasm of colon and/or rectum
|
|
0.100 |
GeneticVariation
|
BEFREE |
<i>BRAF</i> (v-raf murine sarcoma viral oncogene homolog B1) V600E mutant colorectal cancer is associated with short survival.
|
30719102 |
2019 |
|
Malignant neoplasm of colon and/or rectum
|
|
0.100 |
GeneticVariation
|
BEFREE |
3'-Deoxy-3'-18F-fluorothymidine PET predicts response to (V600E)BRAF-targeted therapy in preclinical models of colorectal cancer.
|
23341544 |
2013 |
|
Malignant neoplasm of colon and/or rectum
|
|
0.100 |
GeneticVariation
|
BEFREE |
Alterations in <i>MEK1/2</i> occur in cancers, both in the treatment-naïve state and following targeted therapies, most notably BRAF and MEK inhibitors in <i>BRAF</i>-V600E-mutant melanoma and colorectal cancer.
|
28655712 |
2017 |
|
Malignant neoplasm of colon and/or rectum
|
|
0.100 |
GeneticVariation
|
BEFREE |
An MAFG-containing corepressor complex induces CIMP in BRAF(V600E)-positive colorectal cancer.
|
25367952 |
2014 |
|
Malignant neoplasm of colon and/or rectum
|
|
0.100 |
GeneticVariation
|
BEFREE |
Association between methylation in mismatch repair genes, V600E BRAF mutation and microsatellite instability in colorectal cancer patients.
|
21681432 |
2012 |
|
Malignant neoplasm of colon and/or rectum
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF V600E is the predominantly occurring mutation of the cytoplasmic kinase BRAF, and, in colorectal cancer, its determination provides a diagnostic exclusion criterion for hereditary nonpolyposis colorectal cancer.
|
19213871 |
2009 |
|
Malignant neoplasm of colon and/or rectum
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF V600E mutation in colorectal cancer is associated with right-sided tumours and iron deficiency anaemia.
|
25862899 |
2015 |
|
Malignant neoplasm of colon and/or rectum
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF V600E Mutant Colorectal Cancer Subtypes Based on Gene Expression.
|
27354468 |
2017 |
|
Malignant neoplasm of colon and/or rectum
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF was mutated in 7.6% (484 of 6353) of colorectal cancer and 9.1% (29 of 317) of SBA samples, but V600E mutations were much less common in SBA, representing only 10.3% (3 of 29) of BRAF-mutated cases.
|
28617917 |
2017 |
|
Malignant neoplasm of colon and/or rectum
|
|
0.100 |
GeneticVariation
|
BEFREE |
CIMP-specific inactivation of BRAF(V600E)-induced senescence and apoptosis pathways by IGFBP7 DNA hypermethylation might create a favorable context for the acquisition of BRAF(V600E) in CIMP+ colorectal cancer.
|
20027224 |
2009 |
|
Malignant neoplasm of colon and/or rectum
|
|
0.100 |
GeneticVariation
|
BEFREE |
Circulating 25(OH)D was also inversely associated with <i>BRAF</i> V600E-positive colorectal cancer (per 25 nmol/L increment: HR, 0.71; 95% CI, 0.50-1.01).
|
30842127 |
2019 |
|
Malignant neoplasm of colon and/or rectum
|
|
0.100 |
GeneticVariation
|
BEFREE |
Clinical Significance of BRAF Non-V600E Mutations in Colorectal Cancer: A Retrospective Study of Two Institutions.
|
30463788 |
2018 |
|
Malignant neoplasm of colon and/or rectum
|
|
0.100 |
GeneticVariation
|
BEFREE |
Common BRAF(V600E)-directed pathway mediates widespread epigenetic silencing in colorectal cancer and melanoma.
|
26787892 |
2016 |
|
Malignant neoplasm of colon and/or rectum
|
|
0.100 |
GeneticVariation
|
BEFREE |
Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of BRAF(V600E) colorectal cancer.
|
23549875 |
2013 |
|
Malignant neoplasm of colon and/or rectum
|
|
0.100 |
GeneticVariation
|
BEFREE |
Concomitant with such properties, EBI-907 exhibits potent and selective cytotoxicity against a broader range of BRAF(V600E)-dependent cell lines including certain colorectal cancer cell lines with innate resistance to Vemurafenib.
|
26810733 |
2016 |
|
Malignant neoplasm of colon and/or rectum
|
|
0.100 |
GeneticVariation
|
BEFREE |
Current clinical guidelines recommend mutation analysis for select codons in KRAS and NRAS exons 2, 3, and 4 and BRAF V600E to guide therapy selection and prognostic stratification in advanced colorectal cancer.
|
31589789 |
2020 |
|
Malignant neoplasm of colon and/or rectum
|
|
0.100 |
GeneticVariation
|
BEFREE |
Detection of BRAF V600E mutation in colorectal cancer: comparison of automatic sequencing and real-time chemistry methodology.
|
17065421 |
2006 |
|
Malignant neoplasm of colon and/or rectum
|
|
0.100 |
GeneticVariation
|
BEFREE |
Detection of the V600E hotspot mutation in BRAF oncogene is extremely useful for the screening of hereditary non-polyposis colorectal cancer (Lynch's syndrome) and for the prediction of sensitivity to MEK inhibitors.
|
18428050 |
2008 |
|
Malignant neoplasm of colon and/or rectum
|
|
0.100 |
GeneticVariation
|
BEFREE |
Detection of the BRAF V600E mutation in colorectal cancer by immunohistochemistry is a viable alternative to molecular methods.
|
23650027 |
2013 |
|
Malignant neoplasm of colon and/or rectum
|
|
0.100 |
GeneticVariation
|
BEFREE |
Detection of the BRAF V600E Mutation in Colorectal Cancer by NIR Spectroscopy in Conjunction with Counter Propagation Artificial Neural Network.
|
31208050 |
2019 |
|
Malignant neoplasm of colon and/or rectum
|
|
0.100 |
GeneticVariation
|
BEFREE |
Distinct BRAF (V600E) and KRAS mutations in high microsatellite instability sporadic colorectal cancer in African Americans.
|
19190129 |
2009 |
|
Malignant neoplasm of colon and/or rectum
|
|
0.100 |
GeneticVariation
|
BEFREE |
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E-Mutated Colorectal Cancer.
|
31566309 |
2019 |
|
Malignant neoplasm of colon and/or rectum
|
|
0.100 |
GeneticVariation
|
BEFREE |
Family history of colorectal cancer in BRAF p.V600E-mutated colorectal cancer cases.
|
23462926 |
2013 |
|
Malignant neoplasm of colon and/or rectum
|
|
0.100 |
GeneticVariation
|
BEFREE |
Here, we discuss the current commonly used predictive pharmacogenetic biomarkers in clinical oncology molecular testing: BRAF V600E for vemurafenib in melanoma; EML4-ALK for crizotinib and EGFR for erlotinib and gefitinib in non-small-cell lung cancer; KRAS against the use of cetuximab and panitumumab in colorectal cancer; ERBB2 (HER2/neu) for trastuzumab in breast cancer; BCR-ABL for tyrosine kinase inhibitors in chronic myeloid leukemia; and PML/RARα for all-trans-retinoic acid and arsenic trioxide treatment for acute promyelocytic leukemia.
|
22845480 |
2012 |
|
Malignant neoplasm of colon and/or rectum
|
|
0.100 |
GeneticVariation
|
BEFREE |
Here, we investigate molecular responses upon single and multi-target treatments, over time, using BRAF(V600E) mutant colorectal cancer cells as a model system.
|
29970458 |
2018 |